A 48-year-old woman from Mumbai undergoes wide local excision (WLE) for a 1.8 cm invasive lobular carcinoma (ILC) of the left breast. Final histopathology shows clear margins (>5 mm), no lymphovascular invasion, and sentinel lymph node biopsy is negative (0/2 nodes). Tumour is ER/PR positive, HER2 negative. She is anxious about recurrence. What is the most appropriate next step in management?

Explanation

## Clinical Staging **Key Point:** This patient has: - **T1c** (1.8 cm invasive carcinoma) - **N0** (negative sentinel lymph node biopsy) - **M0** (no distant metastases mentioned; assume staging done) - **Stage IIA** breast cancer - **ER/PR positive, HER2 negative** (luminal A phenotype) ## Adjuvant Therapy Decision ### Role of Radiotherapy **High-Yield:** After breast-conserving therapy (WLE), adjuvant radiotherapy is **mandatory** to reduce local recurrence and improve overall survival. This applies to all patients undergoing WLE, regardless of nodal status or molecular subtype. **Clinical Pearl:** Radiotherapy after WLE reduces 10-year local recurrence from ~20% to ~5% and improves overall survival by ~3–5%. ### Role of Systemic Therapy | Factor | Chemotherapy Indication | Hormonal Therapy Indication | |--------|-------------------------|-----------------------------| | **Nodal status** | N0, small tumour → usually NOT indicated | N0, ER/PR+ → INDICATED | | **Tumour size** | <2 cm, grade I–II, N0 → low risk | ER/PR+ → always indicated | | **Molecular subtype** | Luminal A (ER+, HER2−) → low risk | Luminal A → essential | | **Age** | Premenopausal: consider if high-risk features | Premenopausal: tamoxifen 5–10 years | | | Postmenopausal: rarely indicated | Postmenopausal: AI ± tamoxifen | **Mnemonic:** **CHART** — **C**hemotherapy (high-risk N+, HER2+, triple-negative), **H**ormonal therapy (ER/PR+), **A**ge (premenopausal), **R**adiotherapy (after WLE), **T**argeted therapy (HER2+) ## Decision Algorithm ```mermaid flowchart TD A[Stage I-II breast cancer, ER/PR+, HER2−, N0]:::outcome --> B[WLE performed with clear margins]:::action B --> C{Radiotherapy indicated?}:::decision C -->|Yes: all WLE patients| D[Adjuvant whole breast radiotherapy]:::action D --> E{Chemotherapy indicated?}:::decision E -->|No: T1-2, N0, grade I-II| F[Hormonal therapy only]:::action E -->|Yes: high-risk features| G[Chemotherapy + hormonal therapy]:::action F --> H[Tamoxifen if premenopausal, AI if postmenopausal]:::action G --> H ``` ## Why This Patient Needs Radiotherapy + Hormonal Therapy 1. **Radiotherapy** is non-negotiable after WLE; it reduces local recurrence and improves survival 2. **Hormonal therapy** is indicated because the tumour is ER/PR positive; it reduces distant recurrence and improves survival 3. **Chemotherapy is NOT indicated** because: - Tumour size <2 cm - Grade II (not high-grade) - Node-negative - Luminal A phenotype (low risk) - Oncotype DX score would likely be low (if available) **Clinical Pearl:** In ER/PR+ N0 disease, hormonal therapy alone (without chemotherapy) is often sufficient for early-stage tumours. Radiotherapy is separate and mandatory after WLE. [cite:Harrison 21e Ch 297]